Clinical Trial Update: Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating a single dose of PAZ-417 in healthy Japanese subjects has completed, assessing safety, tolerability and activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PAZ-417

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer Disease, Healthy | Phase 1 | Status: COMPLETED